<DOC>
	<DOCNO>NCT01018511</DOCNO>
	<brief_summary>Clinical study examine efficacy , safety tolerability combination therapy tamsulosin hydrochloride solifenacin succinate compare monotherapy tamsulosin hydrochloride treatment male LUTS associate BPH substantial storage component .</brief_summary>
	<brief_title>Study Solifenacin Succinate Tamsulosin Hydrochloride OCAS Males With Lower Urinary Tract Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<criteria>Voiding storage symptom diagnose LUTS associate BPH ≥ 3 month A total International Prostate Symptom Score ( IPSS ) ≥13 A maximum urinary flow rate ≥4.0 mL/s ≤12.0 mL/s , void volume ≥120 mL free flow A micturition frequency ≥8 least 2 episode urgency Patient Perception Intensity Urgency Scale grade 3 4 per day average 3 day micturition diary ( randomization ) Any significant Post Void Residual volume ( &gt; 150 mL ) A prostate estimate weight ≥75 ml assess transvesical transrectal ultrasound Evidence symptomatic urinary tract infection</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EC905</keyword>
	<keyword>Solifenacin succinate</keyword>
	<keyword>Tamsulosin hydrochloride OCAS</keyword>
	<keyword>Treatment</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Vesomni</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
</DOC>